US6103258A
(en)
*
|
1996-04-12 |
2000-08-15 |
Simon; David Lew |
Salts and bases of the 17-(Cyclopropylmethyl)-4,5 alpha-epoxy-6-Methylenemorphinan-3,14 diol molecule for optimizing dopamine homeostasis during administration of opioid analgesics
|
DE19651551C2
(de)
*
|
1996-12-11 |
2000-02-03 |
Klinge Co Chem Pharm Fab |
Opioidantagonisthaltige galenische Formulierung
|
SK282549B6
(sk)
*
|
1997-02-14 |
2002-10-08 |
G�decke Aktiengesellschaft |
Spôsob stabilizácie naloxonhydrochloridu
|
US6559158B1
(en)
|
1997-11-03 |
2003-05-06 |
Ur Labs, Inc. |
Use of methylnaltrexone and related compounds to treat chronic opioid use side affects
|
US6274591B1
(en)
*
|
1997-11-03 |
2001-08-14 |
Joseph F. Foss |
Use of methylnaltrexone and related compounds
|
US20030158220A1
(en)
*
|
1997-11-03 |
2003-08-21 |
Foss Joseph F. |
Use of methylnaltrexone and related compounds to treat chronic opioid use side effects
|
CA2314893C
(en)
*
|
1997-12-22 |
2005-09-13 |
Euro-Celtique, S.A. |
Opioid agonist/antagonist combinations
|
US6375957B1
(en)
|
1997-12-22 |
2002-04-23 |
Euro-Celtique, S.A. |
Opioid agonist/opioid antagonist/acetaminophen combinations
|
CN1204890C
(zh)
*
|
1997-12-22 |
2005-06-08 |
欧罗赛铁克股份有限公司 |
防止阿片样物质滥用的方法
|
IT1302682B1
(it)
*
|
1998-10-16 |
2000-09-29 |
Formenti Farmaceutici Spa |
Composizioni farmaceutiche orali contenenti buprenorfina
|
US20090297602A1
(en)
*
|
1998-11-02 |
2009-12-03 |
Devane John G |
Modified Release Loxoprofen Compositions
|
US6835194B2
(en)
*
|
1999-03-18 |
2004-12-28 |
Durect Corporation |
Implantable devices and methods for treatment of pain by delivery of fentanyl and fentanyl congeners
|
US6541021B1
(en)
|
1999-03-18 |
2003-04-01 |
Durect Corporation |
Devices and methods for pain management
|
JP2002544221A
(ja)
*
|
1999-05-13 |
2002-12-24 |
ユニハート コーポレーション |
アポコデインおよび/またはその誘導体を含んでなる医薬組成物
|
US10179130B2
(en)
|
1999-10-29 |
2019-01-15 |
Purdue Pharma L.P. |
Controlled release hydrocodone formulations
|
RU2230556C2
(ru)
|
1999-10-29 |
2004-06-20 |
Эро-Селтик, С.А. |
Препаративные формы гидрокодона с контролируемым высвобождением
|
BR0108379A
(pt)
|
2000-02-08 |
2002-11-05 |
Euro Celtique Sa |
Composições de liberação controlada contendo agonista e antagonista opióide, método para a preparação de uma formulação em dosagem de analgésico opióide de liberação controlada com potência analgésica aumentada e sistema de administração através da derme para um analgésico opióide
|
US6716449B2
(en)
|
2000-02-08 |
2004-04-06 |
Euro-Celtique S.A. |
Controlled-release compositions containing opioid agonist and antagonist
|
US7074803B2
(en)
*
|
2001-03-02 |
2006-07-11 |
Durect Corporation |
Opioid formulations
|
CZ20023637A3
(cs)
|
2000-04-07 |
2003-02-12 |
Tap Pharmaceutical Products, Inc. |
Deriváty apomorfinu a způsoby jejich použití
|
WO2001097780A2
(en)
*
|
2000-06-22 |
2001-12-27 |
Pharmasol Ltd |
Pharmaceutical compositions comprising an opioid analgesic
|
AU2002227383B2
(en)
|
2000-10-30 |
2004-07-08 |
Euro-Celtique S.A. |
Controlled release hydrocodone formulations
|
IL155667A0
(en)
|
2000-11-15 |
2003-11-23 |
Tap Pharmaceutical Prod Inc |
Treatment of anti-depression drug-induced sexual dysfunction with apomorphine
|
UA81224C2
(uk)
*
|
2001-05-02 |
2007-12-25 |
Euro Celtic S A |
Дозована форма оксикодону та її застосування
|
US20110104214A1
(en)
|
2004-04-15 |
2011-05-05 |
Purdue Pharma L.P. |
Once-a-day oxycodone formulations
|
CA2778114A1
(en)
*
|
2001-05-11 |
2002-11-21 |
Endo Pharmaceuticals, Inc. |
Abuse-resistant opioid dosage form
|
DE60238756D1
(de)
|
2001-05-11 |
2011-02-10 |
Endo Pharmaceuticals Inc |
Opioid enthaltende arzneiform gegen missbrauch
|
AU2002339378A1
(en)
*
|
2001-05-22 |
2002-12-03 |
Euro-Celtique |
Compartmentalized dosage form
|
ATE446751T1
(de)
*
|
2001-06-05 |
2009-11-15 |
Univ Chicago |
Verwendung von methylnaltrexon zur behandlung von immunsuppression
|
AU2002316738B2
(en)
*
|
2001-07-18 |
2009-01-08 |
Euro-Celtique S.A. |
Pharmaceutical combinations of oxycodone and naloxone
|
WO2003013433A2
(en)
*
|
2001-08-06 |
2003-02-20 |
Euro-Celtique S.A. |
Sequestered antagonist formulations
|
US20030044458A1
(en)
*
|
2001-08-06 |
2003-03-06 |
Curtis Wright |
Oral dosage form comprising a therapeutic agent and an adverse-effect agent
|
US20030068375A1
(en)
|
2001-08-06 |
2003-04-10 |
Curtis Wright |
Pharmaceutical formulation containing gelling agent
|
HUP0401191A3
(en)
|
2001-08-06 |
2006-11-28 |
Euro Celtique Sa |
Opioid agonist formulations with releasable and sequestered antagonist and process for their preparation
|
US20040253310A1
(en)
|
2001-09-21 |
2004-12-16 |
Gina Fischer |
Morphine polymer release system
|
EP2957281A1
(de)
|
2001-09-21 |
2015-12-23 |
Egalet Ltd. |
Polymer-freigabe-system
|
US20140271788A1
(en)
|
2013-03-15 |
2014-09-18 |
Monosol Rx, Llc |
Sublingual and buccal film compositions
|
EP2236161A1
(de)
|
2001-10-18 |
2010-10-06 |
Nektar Therapeutics |
Polymerkonjugate von Opioid-Antagonisten
|
US8329217B2
(en)
|
2001-11-06 |
2012-12-11 |
Osmotica Kereskedelmi Es Szolgaltato Kft |
Dual controlled release dosage form
|
US20030185882A1
(en)
|
2001-11-06 |
2003-10-02 |
Vergez Juan A. |
Pharmaceutical compositions containing oxybutynin
|
US20040033253A1
(en)
*
|
2002-02-19 |
2004-02-19 |
Ihor Shevchuk |
Acyl opioid antagonists
|
CA2478558C
(en)
*
|
2002-03-14 |
2012-09-11 |
Euro-Celtique, S.A. |
Naltrexone hydrochloride compositions
|
EP1492506B2
(de)
|
2002-04-05 |
2016-06-29 |
Euro-Celtique S.A. |
Matrix für die modifizierte freigabe von aktiven substanzen
|
US20050215552A1
(en)
*
|
2002-05-17 |
2005-09-29 |
Gadde Kishore M |
Method for treating obesity
|
RU2004134728A
(ru)
*
|
2002-05-31 |
2005-06-10 |
Алза Корпорейшн (Us) |
Дозированные формы и композиции для осмотической доставки различных дозировок оксикодона
|
US7776314B2
(en)
|
2002-06-17 |
2010-08-17 |
Grunenthal Gmbh |
Abuse-proofed dosage system
|
DK1526848T3
(da)
*
|
2002-08-09 |
2007-10-22 |
Gruenenthal Gmbh |
Opiod-receptorantagonister i transdermale systemer med buprenorphin
|
SI1551372T1
(en)
*
|
2002-09-20 |
2018-08-31 |
Alpharma Pharmaceuticals Llc |
SUBVENCATION DATA AND RELATED CONSTRUCTIONS AND PROCEDURES
|
EP1545468A4
(de)
*
|
2002-09-20 |
2007-06-20 |
Alpharma Inc |
Opioid-formulierungen mit verz gerter freisetzung und anwendungsverfahren
|
DE10250087A1
(de)
*
|
2002-10-25 |
2004-05-06 |
Grünenthal GmbH |
Gegen Missbrauch gesicherte Darreichungsform
|
US20050191244A1
(en)
*
|
2002-10-25 |
2005-09-01 |
Gruenenthal Gmbh |
Abuse-resistant pharmaceutical dosage form
|
DE10250088A1
(de)
*
|
2002-10-25 |
2004-05-06 |
Grünenthal GmbH |
Gegen Missbrauch gesicherte Darreichungsform
|
US20050186139A1
(en)
*
|
2002-10-25 |
2005-08-25 |
Gruenenthal Gmbh |
Abuse-proofed dosage form
|
DE10250084A1
(de)
*
|
2002-10-25 |
2004-05-06 |
Grünenthal GmbH |
Gegen Missbrauch gesicherte Darreichungsform
|
US20040102476A1
(en)
*
|
2002-11-25 |
2004-05-27 |
Chan Tai Wah |
High concentration formulations of opioids and opioid derivatives
|
US8293799B2
(en)
*
|
2003-12-29 |
2012-10-23 |
Osmotica Keresleedelmo és Szolgáltató KFT |
Osmotic device containing a venlafaxine salt and a salt having an ion in common
|
US20070077301A1
(en)
*
|
2002-12-23 |
2007-04-05 |
Meyer Glenn A |
Venlafaxine osmotic device formulation
|
EP2301526B1
(de)
|
2003-03-26 |
2016-03-23 |
Egalet Ltd. |
System zur kontrollierten Freisetzung von Morphin
|
US20040202717A1
(en)
*
|
2003-04-08 |
2004-10-14 |
Mehta Atul M. |
Abuse-resistant oral dosage forms and method of use thereof
|
JP2006522817A
(ja)
*
|
2003-04-08 |
2006-10-05 |
プロジェニックス ファーマシューティカルズ,インコーポレーテッド |
過敏性腸症候群を処置するための末梢オピオイドアンタゴニスト、特にメチルナルトレキソンの使用
|
DK2368554T3
(en)
*
|
2003-04-08 |
2015-01-26 |
Progenics Pharm Inc |
A pharmaceutical composition comprising methylnaltrexone
|
WO2004091665A1
(en)
*
|
2003-04-08 |
2004-10-28 |
Progenics Pharmaceuticals, Inc. |
Combination therapy for constipation comprising a laxative and a peripheral opioid antagonist
|
TWI347201B
(en)
|
2003-04-21 |
2011-08-21 |
Euro Celtique Sa |
Pharmaceutical products,uses thereof and methods for preparing the same
|
WO2004096201A1
(en)
|
2003-04-29 |
2004-11-11 |
Orexigen Therapeutics, Inc. |
Compositions for affecting weight loss
|
US8790689B2
(en)
|
2003-04-30 |
2014-07-29 |
Purdue Pharma L.P. |
Tamper resistant transdermal dosage form
|
MY141815A
(en)
*
|
2003-04-30 |
2010-06-30 |
Purdue Pharma Lp |
Tamper-resistant transdermal dosage form comprising an active agent component and an adverse agent component at the distal site of the active agent layer
|
DE10336400A1
(de)
*
|
2003-08-06 |
2005-03-24 |
Grünenthal GmbH |
Gegen Missbrauch gesicherte Darreichungsform
|
DE102005005446A1
(de)
*
|
2005-02-04 |
2006-08-10 |
Grünenthal GmbH |
Bruchfeste Darreichungsformen mit retardierter Freisetzung
|
US8075872B2
(en)
*
|
2003-08-06 |
2011-12-13 |
Gruenenthal Gmbh |
Abuse-proofed dosage form
|
DE102004020220A1
(de)
*
|
2004-04-22 |
2005-11-10 |
Grünenthal GmbH |
Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform
|
US20070048228A1
(en)
|
2003-08-06 |
2007-03-01 |
Elisabeth Arkenau-Maric |
Abuse-proofed dosage form
|
DE102004032051A1
(de)
*
|
2004-07-01 |
2006-01-19 |
Grünenthal GmbH |
Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform
|
PL1658054T3
(pl)
*
|
2003-08-06 |
2007-11-30 |
Gruenenthal Gmbh |
Postać aplikacyjna zabezpieczona przed nadużyciem
|
DE10361596A1
(de)
*
|
2003-12-24 |
2005-09-29 |
Grünenthal GmbH |
Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
|
JP4758897B2
(ja)
*
|
2003-09-25 |
2011-08-31 |
ユーロ−セルティーク エス.エイ. |
ヒドロコドンとナルトレキソンとの併用医薬
|
WO2005030181A1
(en)
*
|
2003-09-26 |
2005-04-07 |
Alza Corporation |
Controlled release formulations of opioid and nonopioid analgesics
|
KR20060115860A
(ko)
*
|
2003-09-26 |
2006-11-10 |
알자 코포레이션 |
활성 제제의 서방성 전달을 위한 oros 푸시-스틱
|
WO2005072079A2
(en)
*
|
2003-09-26 |
2005-08-11 |
Alza Coporation |
Drug coating providing high drug loading and methods for providing the same
|
US20060182692A1
(en)
|
2003-12-16 |
2006-08-17 |
Fishburn C S |
Chemically modified small molecules
|
CN1925875A
(zh)
*
|
2003-12-16 |
2007-03-07 |
尼克塔治疗亚拉巴马公司 |
化学改性的小分子
|
EP1604666A1
(de)
*
|
2004-06-08 |
2005-12-14 |
Euro-Celtique S.A. |
Opioide zur Behandlung der chronischen obstruktiven Lungenkrankheit
|
PT1765292T
(pt)
|
2004-06-12 |
2017-12-29 |
Collegium Pharmaceutical Inc |
Formulações de fármacos dissuasoras de abuso
|
CA2572352A1
(en)
*
|
2004-07-01 |
2006-01-12 |
Gruenenthal Gmbh |
Oral dosage form safeguarded against abuse containing (1r,2r)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol
|
DE102004032103A1
(de)
*
|
2004-07-01 |
2006-01-19 |
Grünenthal GmbH |
Gegen Missbrauch gesicherte, orale Darreichungsform
|
DE102004032049A1
(de)
*
|
2004-07-01 |
2006-01-19 |
Grünenthal GmbH |
Gegen Missbrauch gesicherte, orale Darreichungsform
|
FI1765303T4
(fi)
*
|
2004-07-01 |
2023-01-31 |
|
Väärinkäytöltä suojattu oraalinen tabletti
|
US8541026B2
(en)
*
|
2004-09-24 |
2013-09-24 |
Abbvie Inc. |
Sustained release formulations of opioid and nonopioid analgesics
|
AR053986A1
(es)
|
2004-12-03 |
2007-05-30 |
Osmotica Pharmaceutical Argent |
Dispositivo osmotico que contiene amantadina y una sal osmotica
|
WO2006078842A1
(en)
*
|
2005-01-20 |
2006-07-27 |
Progenics Pharmaceuticals, Inc. |
Use of methylnaltrexone and related compounds to treat post-operative gastrointestinal dysfunction
|
DE102005005449A1
(de)
*
|
2005-02-04 |
2006-08-10 |
Grünenthal GmbH |
Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
|
EP1702558A1
(de)
|
2005-02-28 |
2006-09-20 |
Euro-Celtique S.A. |
Verfahren und Vorrichtung zur Darmtätigkeitserfassung
|
MX2007010833A
(es)
|
2005-03-07 |
2009-02-17 |
Univ Chicago |
Uso de antagonistas opioides para atenuar proliferacion y migracion de células endoteliales.
|
US8518962B2
(en)
|
2005-03-07 |
2013-08-27 |
The University Of Chicago |
Use of opioid antagonists
|
US9662325B2
(en)
|
2005-03-07 |
2017-05-30 |
The University Of Chicago |
Use of opioid antagonists to attenuate endothelial cell proliferation and migration
|
US8524731B2
(en)
|
2005-03-07 |
2013-09-03 |
The University Of Chicago |
Use of opioid antagonists to attenuate endothelial cell proliferation and migration
|
AR057035A1
(es)
|
2005-05-25 |
2007-11-14 |
Progenics Pharm Inc |
SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
|
AR057325A1
(es)
|
2005-05-25 |
2007-11-28 |
Progenics Pharm Inc |
Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
|
US20080194611A1
(en)
*
|
2005-06-03 |
2008-08-14 |
Alverdy John C |
Modulation of Cell Barrier Dysfunction
|
EP2135603B1
(de)
*
|
2005-11-22 |
2013-01-02 |
Orexigen Therapeutics, Inc. |
Zusammensetzungen und Verfahren zur Erhöhung der Insulinsensitivität
|
EP1810678A1
(de)
*
|
2006-01-19 |
2007-07-25 |
Holger Lars Hermann |
Verwendung einer Kombination von Morphin und Naloxon zur Drogensubstitution
|
US20090022798A1
(en)
*
|
2007-07-20 |
2009-01-22 |
Abbott Gmbh & Co. Kg |
Formulations of nonopioid and confined opioid analgesics
|
US20090317355A1
(en)
*
|
2006-01-21 |
2009-12-24 |
Abbott Gmbh & Co. Kg, |
Abuse resistant melt extruded formulation having reduced alcohol interaction
|
US20100172989A1
(en)
*
|
2006-01-21 |
2010-07-08 |
Abbott Laboratories |
Abuse resistant melt extruded formulation having reduced alcohol interaction
|
US8916195B2
(en)
|
2006-06-05 |
2014-12-23 |
Orexigen Therapeutics, Inc. |
Sustained release formulation of naltrexone
|
DK2526932T3
(en)
*
|
2006-06-19 |
2017-07-17 |
Alpharma Pharmaceuticals Llc |
Pharmaceutical composition
|
SA07280459B1
(ar)
|
2006-08-25 |
2011-07-20 |
بيورديو فارما إل. بي. |
أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
|
EP1897543A1
(de)
|
2006-08-30 |
2008-03-12 |
Euro-Celtique S.A. |
Buprenorphine-Waffel zur Substitutionstherapie
|
TW200817048A
(en)
*
|
2006-09-08 |
2008-04-16 |
Wyeth Corp |
Dry powder compound formulations and uses thereof
|
EP2073797A2
(de)
*
|
2006-10-11 |
2009-07-01 |
Alpharma, Inc. |
Pharmazeutische zusammensetzungen
|
US20080125592A1
(en)
*
|
2006-10-17 |
2008-05-29 |
Penick Corporation |
Process for preparing oxymorphone, naltrexone, and buprenorphine
|
CA2674915C
(en)
*
|
2006-10-17 |
2015-06-30 |
Penick Corporation |
Process for preparing oxymorphone
|
KR20180066272A
(ko)
|
2006-11-09 |
2018-06-18 |
오렉시젠 세러퓨틱스 인크. |
단위 용량 팩키지
|
TWI609702B
(zh)
|
2006-11-09 |
2018-01-01 |
歐瑞根治療有限公司 |
層狀醫藥調配物
|
DE102007011485A1
(de)
*
|
2007-03-07 |
2008-09-11 |
Grünenthal GmbH |
Darreichungsform mit erschwertem Missbrauch
|
CA2865661C
(en)
|
2007-03-29 |
2016-05-17 |
Progenics Pharmaceuticals, Inc. |
Peripheral opioid receptor antagonists and uses thereof
|
CN101801979A
(zh)
|
2007-03-29 |
2010-08-11 |
普罗热尼奇制药公司 |
(r)-n-溴化甲基纳曲酮的晶体形式及其用途
|
SI2565195T1
(sl)
|
2007-03-29 |
2015-09-30 |
Wyeth Llc |
Periferalni opioidni receptorji in antagonisti in njih uporaba
|
WO2008148798A2
(en)
|
2007-06-04 |
2008-12-11 |
Egalet A/S |
Controlled release pharmaceutical compositions for prolonged effect
|
DK2197429T3
(en)
|
2007-09-03 |
2016-05-30 |
Nanotherapeutics Inc |
Particulate compositions for delivery of poorly soluble drugs
|
AU2008296905A1
(en)
*
|
2007-09-04 |
2009-03-12 |
Alpharma Pharmaceuticals, Llc |
A multilayer pharmaceutical composition comprising an antagonist in a first layer and an agonist in a second layer
|
AU2014250614B2
(en)
*
|
2007-09-04 |
2016-11-10 |
Alpharma Pharmaceuticals, Llc |
A multilayer pharmaceutical composition comprising an antagonist in a first layer and an agonist in a second layer
|
US8486448B2
(en)
|
2007-12-17 |
2013-07-16 |
Paladin Labs Inc. |
Misuse preventative, controlled release formulation
|
EP2224808A4
(de)
*
|
2007-12-17 |
2013-11-27 |
Alpharma Pharmaceuticals Llc |
Pharmazeutische zusammensetzung
|
CA2709903A1
(en)
*
|
2007-12-17 |
2009-06-25 |
Alpharma Pharmaceuticals, Llc |
Oral opioid compositions with opioid antagonist
|
AU2008343267A1
(en)
*
|
2007-12-17 |
2009-07-09 |
Alpharma Pharmaceuticals, Llc |
Pharmaceutical composition
|
EP2224805A4
(de)
*
|
2007-12-17 |
2013-10-16 |
Alpharma Pharmaceuticals Llc |
Pharmazeutische zusammensetzung
|
US8623418B2
(en)
|
2007-12-17 |
2014-01-07 |
Alpharma Pharmaceuticals Llc |
Pharmaceutical composition
|
AU2015200313B2
(en)
*
|
2007-12-17 |
2016-12-01 |
Alpharma Pharmaceuticals, Llc |
Pharmaceutical composition
|
US20100151014A1
(en)
*
|
2008-12-16 |
2010-06-17 |
Alpharma Pharmaceuticals, Llc |
Pharmaceutical composition
|
EP2249811A1
(de)
|
2008-01-25 |
2010-11-17 |
Grünenthal GmbH |
Pharmazeutische dosierform
|
US20090246276A1
(en)
|
2008-01-28 |
2009-10-01 |
Graham Jackson |
Pharmaceutical Compositions
|
JP5358587B2
(ja)
|
2008-02-06 |
2013-12-04 |
プロジェニックス・ファーマシューティカルス・インコーポレイテッド |
(r),(r)−2,2’−ビス−メチルナルトレキソンの製造及び用途
|
JP2011511782A
(ja)
|
2008-02-12 |
2011-04-14 |
アボット・ラボラトリーズ |
長期放出性ヒドロコドンアセトアミノフェンならびにその関連方法および用途
|
CA2719134C
(en)
*
|
2008-03-21 |
2015-06-30 |
The University Of Chicago |
Treatment with opioid antagonists and mtor inhibitors
|
JP5571069B2
(ja)
*
|
2008-05-05 |
2014-08-13 |
ユーロ−セルティーク エス.エイ. |
皮膚病変を治療するためのオピオイド組成物
|
EP2273983B1
(de)
|
2008-05-09 |
2016-07-20 |
Grünenthal GmbH |
Verfahren für die zubereitung eines pulverförmigen zwischenprodukts und einer endgültigen festen darreichungsform anhand eines sprüherstarrungsschrittes
|
MX2010012909A
(es)
*
|
2008-05-30 |
2011-02-25 |
Orexigen Therapeutics Inc |
Metodos para tratamiento de condiciones de grasa visceral.
|
US20090311335A1
(en)
*
|
2008-06-12 |
2009-12-17 |
Scott Jenkins |
Combination of a triptan and an nsaid
|
CN105456267A
(zh)
*
|
2008-07-07 |
2016-04-06 |
欧洲凯尔特公司 |
阿片类拮抗剂治疗尿潴留的用途
|
CA2676881C
(en)
|
2008-09-30 |
2017-04-25 |
Wyeth |
Peripheral opioid receptor antagonists and uses thereof
|
HUE047438T2
(hu)
|
2008-10-30 |
2020-04-28 |
Gruenenthal Gmbh |
Új és potens tapentadol dózisformák
|
JP5667575B2
(ja)
|
2008-12-16 |
2015-02-12 |
パラディン ラブス インコーポレーテッド |
誤用を防止する放出制御製剤
|
WO2010089132A1
(en)
|
2009-02-06 |
2010-08-12 |
Egalet A/S |
Immediate release composition resistant to abuse by intake of alcohol
|
MX347106B
(es)
|
2009-03-10 |
2017-04-12 |
Euro-Celtique S A * |
Coposiciones farmacéuticas de liberación inmediata que comprenden oxicodona y naloxona.
|
EP2416782A1
(de)
*
|
2009-04-09 |
2012-02-15 |
Alkermes Pharma Ireland Limited |
Clozapinzusammensetzungen mit verzögerter freisetzung
|
NZ597283A
(en)
|
2009-06-24 |
2013-07-26 |
Egalet Ltd |
Controlled release formulations
|
PL2456424T3
(pl)
|
2009-07-22 |
2013-12-31 |
Gruenenthal Gmbh |
Stabilizowana przed utlenianiem odporna na naruszenie postać dawkowania
|
PL2456427T3
(pl)
|
2009-07-22 |
2015-07-31 |
Gruenenthal Gmbh |
Wytłaczana na gorąco postać dawki o kontrolowanym uwalnianiu
|
US10668060B2
(en)
|
2009-12-10 |
2020-06-02 |
Collegium Pharmaceutical, Inc. |
Tamper-resistant pharmaceutical compositions of opioids and other drugs
|
RU2616496C2
(ru)
|
2010-01-11 |
2017-04-17 |
Ориксиджен Терапьютикс, Инк. |
Способы проведения терапии потери веса у пациентов с доминирующей депрессией (варианты)
|
US9579285B2
(en)
*
|
2010-02-03 |
2017-02-28 |
Gruenenthal Gmbh |
Preparation of a powdery pharmaceutical composition by means of an extruder
|
IT1398930B1
(it)
*
|
2010-03-24 |
2013-03-28 |
Molteni & C |
Formulazioni farmaceutiche bistrato contenenti agonisti ed antagonisti oppioidi.
|
WO2012007159A2
(en)
|
2010-07-14 |
2012-01-19 |
Grünenthal GmbH |
Novel gastro-retentive dosage forms
|
MX2013002293A
(es)
|
2010-09-02 |
2013-05-09 |
Gruenenthal Gmbh |
Forma de dosificacion resistente a alteracion que comprende un polimero anionico.
|
AU2011297901B2
(en)
|
2010-09-02 |
2014-07-31 |
Grunenthal Gmbh |
Tamper resistant dosage form comprising inorganic salt
|
EP2446882B8
(de)
|
2010-10-28 |
2014-02-12 |
Acino Pharma AG |
Arzneimittel mit dem Wirkstoff Hydromorphon mit verbesserter Lagerstabilität
|
JP2014504184A
(ja)
|
2010-12-01 |
2014-02-20 |
スパイナル・モデュレーション・インコーポレイテッド |
神経構造への薬剤の直接送達
|
CN103370058A
(zh)
|
2010-12-22 |
2013-10-23 |
普渡制药公司 |
包覆的抗篡改控制释放剂型
|
CA2822769C
(en)
|
2010-12-23 |
2016-10-04 |
Purdue Pharma L.P. |
Tamper resistant solid oral dosage forms
|
US20130028972A1
(en)
|
2011-07-29 |
2013-01-31 |
Grunenthal Gmbh |
Tamper-resistant tablet providing immediate drug release
|
PE20141638A1
(es)
|
2011-07-29 |
2014-11-22 |
Gruenenthal Chemie |
Tableta a prueba de manipulacion que proporciona liberacion de farmaco inmediato
|
EP3939569A1
(de)
|
2011-09-19 |
2022-01-19 |
Orexo AB |
Neue missbrauchssichere pharmazeutische zusammensetzung zur behandlung von opiatsucht
|
KR20140096062A
(ko)
*
|
2011-11-17 |
2014-08-04 |
그뤼넨탈 게엠베하 |
약리학적 활성 성분, 오피오이드 길항제 및/또는 혐오제, 폴리알킬렌 옥사이드 및 음이온성 중합체를 포함하는 탬퍼-저항성 경구 약제학적 투여형
|
CA2853764C
(en)
*
|
2011-11-22 |
2017-05-16 |
Watson Pharmaceuticals, Inc. |
Immediate release abuse deterrent tablet
|
US20130143867A1
(en)
|
2011-12-02 |
2013-06-06 |
Sychroneuron Inc. |
Acamprosate formulations, methods of using the same, and combinations comprising the same
|
US20130225697A1
(en)
|
2012-02-28 |
2013-08-29 |
Grunenthal Gmbh |
Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer
|
EA201401139A1
(ru)
|
2012-04-18 |
2015-03-31 |
Грюненталь Гмбх |
Устойчивая к разрушению и к сбросу дозы фармацевтическая лекарственная форма
|
US10064945B2
(en)
|
2012-05-11 |
2018-09-04 |
Gruenenthal Gmbh |
Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
|
WO2013184837A1
(en)
|
2012-06-06 |
2013-12-12 |
Orexigen Therapeutics, Inc. |
Methods of treating overweight and obesity
|
US9549899B2
(en)
|
2012-07-06 |
2017-01-24 |
Egalet Ltd. |
Abuse deterrent pharmaceutical compositions for controlled release
|
KR101840526B1
(ko)
|
2013-02-05 |
2018-03-20 |
퍼듀 퍼머 엘피 |
내변조성 제약 제제
|
US9517208B2
(en)
|
2013-03-15 |
2016-12-13 |
Purdue Pharma L.P. |
Abuse-deterrent dosage forms
|
US10751287B2
(en)
|
2013-03-15 |
2020-08-25 |
Purdue Pharma L.P. |
Tamper resistant pharmaceutical formulations
|
JP6445537B2
(ja)
|
2013-05-29 |
2018-12-26 |
グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング |
1個または複数の粒子を含有する改変防止(tamper−resistant)剤形
|
MX2015016254A
(es)
|
2013-05-29 |
2016-04-20 |
Gruenenthal Gmbh |
Forma de dosificacion resistente al uso indebido con perfil de liberacion bimodal.
|
EP3003297A4
(de)
|
2013-06-05 |
2017-04-19 |
Synchroneuron Inc. |
Acamprosat-formulierungen, verfahren zur verwendung davon und kombinationen damit
|
JP6449871B2
(ja)
|
2013-07-12 |
2019-01-09 |
グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング |
エチレン−酢酸ビニルポリマーを含有する改変防止剤形
|
CA2918004C
(en)
|
2013-07-23 |
2018-11-20 |
Euro-Celtique S.A. |
A combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation
|
CA2919892C
(en)
|
2013-08-12 |
2019-06-18 |
Pharmaceutical Manufacturing Research Services, Inc. |
Extruded immediate release abuse deterrent pill
|
JP6480936B2
(ja)
|
2013-11-26 |
2019-03-13 |
グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング |
クライオミリングによる粉末状医薬組成物の調製
|
WO2015095391A1
(en)
|
2013-12-17 |
2015-06-25 |
Pharmaceutical Manufacturing Research Services, Inc. |
Extruded extended release abuse deterrent pill
|
US9492444B2
(en)
|
2013-12-17 |
2016-11-15 |
Pharmaceutical Manufacturing Research Services, Inc. |
Extruded extended release abuse deterrent pill
|
WO2015173195A1
(en)
|
2014-05-12 |
2015-11-19 |
Grünenthal GmbH |
Tamper resistant immediate release capsule formulation comprising tapentadol
|
EP3148512A1
(de)
|
2014-05-26 |
2017-04-05 |
Grünenthal GmbH |
Gegen entsorgung von ethanolischer dosis gesicherte mehrfachpartikel
|
US9707184B2
(en)
|
2014-07-17 |
2017-07-18 |
Pharmaceutical Manufacturing Research Services, Inc. |
Immediate release abuse deterrent liquid fill dosage form
|
US9132096B1
(en)
|
2014-09-12 |
2015-09-15 |
Alkermes Pharma Ireland Limited |
Abuse resistant pharmaceutical compositions
|
EP3209282A4
(de)
|
2014-10-20 |
2018-05-23 |
Pharmaceutical Manufacturing Research Services, Inc. |
Missbrauchssichere flüssigkeitsfülldosierform mit verlängerter freisetzung
|
WO2016170097A1
(en)
|
2015-04-24 |
2016-10-27 |
Grünenthal GmbH |
Tamper-resistant dosage form with immediate release and resistance against solvent extraction
|
JP2018526414A
(ja)
|
2015-09-10 |
2018-09-13 |
グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング |
乱用抑止性の即放性製剤を用いた経口過剰摂取に対する保護
|
US20170312226A1
(en)
*
|
2016-04-28 |
2017-11-02 |
Ascent Pharmaceuticals, Inc. |
Pharmaceutical dosage forms
|
WO2017222575A1
(en)
|
2016-06-23 |
2017-12-28 |
Collegium Pharmaceutical, Inc. |
Process of making more stable abuse-deterrent oral formulations
|